Expanding access to advanced therapies for all cancer patients

A universal, off-the-shelf immunotherapy platform personalized in real time, scalable, and designed to overcome the toughest challenges of solid tumors

Two pillars of our strategy:

TRANSFORM

RESOLVE

the cell therapy business model for cancer treatment to reduce manufacturing and logistics costs

the technical limitations why state of the art immune oncology has failed solid tumor patients

Our science

What we do?

Scalable universal cell product engineered to overcome solid tumor heterogeneity and immune escape. Available off-the-shelf at cancer centers.

Our science

Our goal

Potent therapy that is tailored to each patient, available without delays, whenever doctors and patients are ready.

Modulating patient immunity for broader, deeper and durable immune response

For patients → this translates into faster access to a more potent therapy that can both eliminate tumors and reduce recurrence.

For healthcare systems and payers it → delivers scalability and cost-efficiency by removing manufacturing bottlenecks, lowering treatment costs, and enabling reproducible delivery across treatment centers.

Our Team

François Binette PhDCEO/Founder

François is a veteran executive with 30 years of experience in advanced cell and gene herapy product development across multiple therapeutic areas. His background includes leadership roles in both startups and major healthcare organizations. He previously served as President of Renovaro Biosciences, CEO of Rediens, and Global Head of Product Development at Lineage Cell Therapeutics, with prior experience at Johnson & Johnson, Medtronic, and Genzyme.

Smiling older man with white hair and glasses, wearing a blue shirt and black blazer against a plain gray background.

Michael Montgomery, MDCMO/ Co-Founder

Michael is a physician-scientist with over 25 years of experience in internal medicine, developmental biology, and drug development. He has held senior leadership roles in both biotech startups and major pharma, including Centocor, Johnson & Johnson, and Incyte. He co-founded the Proof-of-Concept Team at J&J and led Global Medical Affairs at Incyte.

Vertical gradient background transitioning from dark teal at the top to lighter teal at the bottom.

“Confidential” PHDHead Translational Science

Stealth

Katherine Mercier Fractional COO

Katherine is a biopharmaceutical executive with over 20 years of global experience in Technical Operations, CMC and Quality Assurance across biologics, cell therapies and combination products. She has led teams through clinical and commercial manufacturing, regulatory inspections, and product launches. Before joining Tidewave Bio, Katherine served as Vice President of Technical Operations at Evofem Biosciences and held leadership roles at Vital Therapies, Dendreon, and Sandoz. She is passionate about advancing innovative therapies through robust CMC and GMP strategies that enable seamless scale-up and successful commercialization.

all team members

Have questions?

Want to know more?

We would be delighted to connect and share more about the milestones we have already achieved, the vision driving our work, and the exciting opportunities that lie ahead. Our team is eager to explain how our approach is shaping the future and to explore potential synergies with partners who share our mission.